Study predicting response to pembrolizumab in advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study looks back at prior treatment to learn which patients with advanced non-small cell lung cancer (NSCLC) are more likely to respond to pembrolizumab, an immune therapy given up front. The results may help doctors better predict who benefits from this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older).
- You have advanced non-small cell lung cancer (NSCLC).
- Your tumor test showed PD-L1 “TPS” of 50% or higher.
- You received your first pembrolizumab treatment between January 2017 and December 2019.
- You have not been treated with immunotherapy before pembrolizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests if the immunotherapy drug pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer by boosting the body's own immune cells (T-cells) to fight the cancer. It's for people who have not had any prior cancer treatment.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This trial tests how well a new imaging method and lab-grown tumor models can predict response to immunotherapy in people with non-small cell lung cancer that has returned after initial surgery. Participants will receive standard immunotherapy, and researchers will study their tumor samples and scans.
This trial tests a drug called pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who haven't received treatment for metastatic disease. Researchers will also study your T-cells (a type of immune cell) to see if they can predict how well the drug works.
Hear when a new Advanced Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.